UK markets closed

Sanofi (SAN.PA)

Paris - Paris Delayed price. Currency in EUR
Add to watchlist
85.77-1.68 (-1.92%)
At close: 05:39PM CET
Full screen
Previous close87.45
Open87.10
Bid0.00 x 0
Ask0.00 x 0
Day's range85.24 - 87.24
52-week range76.45 - 106.66
Volume2,170,645
Avg. volume1,825,206
Market cap108.713B
Beta (5Y monthly)0.46
PE ratio (TTM)16.82
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yield3.33 (3.78%)
Ex-dividend date06 May 2022
1y target estN/A
  • Globe Newswire

    Press Release: Statement from Sanofi regarding: rule 2.12 of the takeover rules

    THIS IS AN ANNOUNCEMENT FALLING UNDER RULE 2.12 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 (THE "TAKEOVER RULES"). NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. DECEMBER 2, 2022 Statement from Sanofi regarding: rule 2.12 of the takeover rules Paris, December 2, 2022. As required by Rule 2.12 of the Takeover Rules, Sanofi S.A.

  • Globe Newswire

    Press Release: Acoziborole: Investigational single-dose oral treatment raises hope for elimination of sleeping sickness in Africa

    Acoziborole: Investigational single-dose oral treatment raises hope for elimination of sleeping sickness in Africa Positive Phase II/III study results support acoziborole’s potential in treatment for deadly disease Geneva, Kinshasa, Paris – November 30, 2022. The Drugs for Neglected Diseases initiative (DNDi) and Sanofi announce treatment success rates of up to 95% from a Phase II/III study investigating the safety and efficacy of single-dose acoziborole, a potentially transformative investigati

  • Globe Newswire

    Press Release: European Commission approves Enjaymo® (sutimlimab) for treatment of hemolytic anemia in adult patients with cold agglutinin disease

    European Commission approves Enjaymo® (sutimlimab) for treatment of hemolytic anemia in adult patients with cold agglutinin disease Enjaymo is the first-and-only approved therapeutic option approved for hemolytic anemia in adult patients with cold agglutinin disease Paris, November 17, 2022. The European Commission (EC) has granted marketing authorization for Enjaymo® (sutimlimab) for the treatment of hemolytic anemia in adult patients with cold agglutinin disease (CAD), a rare, serious, and chr